Intensity Therapeutics Selected to Present at BioCentury Future Leaders Conference
WESTPORT, Conn.--(BUSINESS WIRE)-- Intensity Therapeutics, Inc., a privately held biotechnology company developing proprietary immune cell activating anti-cancer drug products, announced that the Company has been selected to present at the 23rd annual Future Leaders in the Biotech Industry conference hosted by BioCentury. Chief Executive Officer Lewis Bender will present an update on the Company and the development status of INT230-6, an immune cell-activating anti-cancer drug candidate. The presentation will take place at 2:30 pm ET on March 11, 2016 in room 402/403 at the Millennium Broadway hotel in New York City, NY.
INT230-6 is a novel, anticancer drug product able to disperse through tumors and diffuse into cancer cells. The product was identified from Intensity’s DfuseRxSM platform technology. Using in vivo preclinical models of severe cancer, INT230-6 treatment results in substantial improvement in overall survival compared to standard therapies. The product can completely clear large tumors in animal models. Complete responders have long-term protection even after multiple re-inoculations of the cancer. INT230-6 administration has shown an increased recruitment of immune cells to the tumor micro-environment.
About Intensity Therapeutics, Inc.
Intensity Therapeutics, Inc. is a biotechnology company whose mission is to greatly extend the lives of patients with cancer. Intensity Therapeutics is pioneering a new immune-based approach to treat cancer - in situ vaccination. The Company uses its DfuseRxSM platform technology to create new products capable of attenuating (killing) a tumor in a manner that allows for the adaptive immune system to recognize the cancer and attack tumors. Further information can be found at www.intensitytherapeutics.com
This press release contains forward-looking statements regarding Intensity Therapeutics’ plans, future operations and objectives. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual performance or achievements to be materially different from those currently anticipated. These forward-looking statements include, among other things, statements about the initiation and timing of future clinical trials.
Intensity Therapeutics, Inc.
Lewis Bender, 203-682-2434
President & CEO
Aline Sherwood, 312-238-8957
Source: Intensity Therapeutics, Inc.
Released March 8, 2016